Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
1.640
-0.020 (-1.20%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Fortress Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 56.68 | 64.99 | 73.07 | 68.79 | 45.6 | Upgrade
|
| Other Revenue | 1 | 19.52 | 2.67 | - | - | Upgrade
|
| Revenue | 57.68 | 84.51 | 75.74 | 68.79 | 45.6 | Upgrade
|
| Revenue Growth (YoY) | -31.76% | 11.58% | 10.11% | 50.86% | 24.49% | Upgrade
|
| Cost of Revenue | 77.76 | 128.96 | 165.65 | 160.95 | 78.7 | Upgrade
|
| Gross Profit | -20.09 | -44.45 | -89.91 | -92.16 | -33.1 | Upgrade
|
| Selling, General & Admin | 84.04 | 87.84 | 113.66 | 86.84 | 61.17 | Upgrade
|
| Other Operating Expenses | -4.55 | - | - | - | - | Upgrade
|
| Operating Expenses | 82.91 | 91.61 | 113.66 | 86.84 | 61.17 | Upgrade
|
| Operating Income | -103 | -136.06 | -203.56 | -179 | -94.27 | Upgrade
|
| Interest Expense | -13.53 | -15.32 | -13.64 | -15.31 | -15.33 | Upgrade
|
| Interest & Investment Income | 2.68 | 3 | 1.4 | 0.65 | 1.52 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.68 | 1.02 | 2.34 | -0.45 | -1.19 | Upgrade
|
| EBT Excluding Unusual Items | -113.16 | -147.35 | -213.46 | -194.11 | -109.27 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 39.29 | 6.42 | Upgrade
|
| Asset Writedown | -7.38 | -6.29 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -9.54 | - | Upgrade
|
| Pretax Income | -120.54 | -153.63 | -213.46 | -164.35 | -102.85 | Upgrade
|
| Income Tax Expense | 0.31 | 0.52 | 0.45 | 0.47 | 0.14 | Upgrade
|
| Earnings From Continuing Operations | -120.86 | -154.15 | -213.91 | -164.83 | -102.99 | Upgrade
|
| Net Income to Company | -120.86 | -154.15 | -213.91 | -164.83 | -102.99 | Upgrade
|
| Minority Interest in Earnings | 74.86 | 93.52 | 127.34 | 100.12 | 56.46 | Upgrade
|
| Net Income | -46 | -60.64 | -86.58 | -64.7 | -46.53 | Upgrade
|
| Preferred Dividends & Other Adjustments | 9.89 | 8.03 | 8.03 | - | - | Upgrade
|
| Net Income to Common | -55.89 | -68.67 | -94.61 | -64.7 | -46.53 | Upgrade
|
| Shares Outstanding (Basic) | 21 | 8 | 6 | 5 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 21 | 8 | 6 | 5 | 5 | Upgrade
|
| Shares Change (YoY) | 156.25% | 36.89% | 8.78% | 13.46% | 31.61% | Upgrade
|
| EPS (Basic) | -2.69 | -8.47 | -15.97 | -11.88 | -9.69 | Upgrade
|
| EPS (Diluted) | -2.69 | -8.47 | -15.97 | -11.88 | -9.69 | Upgrade
|
| Free Cash Flow | -80.19 | -128.29 | -182.12 | -121.11 | -85.61 | Upgrade
|
| Free Cash Flow Per Share | -3.86 | -15.82 | -30.74 | -22.23 | -17.83 | Upgrade
|
| Gross Margin | -34.82% | -52.60% | -118.70% | -133.97% | -72.60% | Upgrade
|
| Operating Margin | -178.58% | -160.99% | -268.76% | -260.21% | -206.74% | Upgrade
|
| Profit Margin | -96.91% | -81.25% | -124.91% | -94.06% | -102.03% | Upgrade
|
| Free Cash Flow Margin | -139.04% | -151.80% | -240.44% | -176.05% | -187.74% | Upgrade
|
| EBITDA | -98.53 | -130.06 | -196.18 | -173.9 | -90.57 | Upgrade
|
| EBITDA Margin | -170.84% | -153.89% | -259.00% | -252.79% | -198.62% | Upgrade
|
| D&A For EBITDA | 4.46 | 6 | 7.39 | 5.1 | 3.7 | Upgrade
|
| EBIT | -103 | -136.06 | -203.56 | -179 | -94.27 | Upgrade
|
| EBIT Margin | -178.58% | -160.99% | -268.76% | -260.21% | -206.74% | Upgrade
|
| Revenue as Reported | 57.68 | 84.51 | 75.74 | 68.79 | 45.6 | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.